GLP Medications: The Class, Products, and Evidence

This page lives in the PlexusDx Education Hub, where we unpack GLP-1 biology, weight-management options, and the genetic factors sitting beneath each choice. Open the Peptides & GLP-1 library.

"GLP medications" is a broad way to name the incretin-based drugs used for glucose and weight. This article defines what qualifies as one, explains how the class works on body weight, reviews the evidence base and where it is published, lists the approved products and their uses, and closes with the safety warnings and genetic terrain beneath them.

What counts as a GLP medication

A GLP medication is a GLP-1 pathway compound in the receptor agonist class — a drug that engages the GLP-1 receptor to reproduce the effects of the natural incretin hormone. The category also includes the GIP/GLP-1 dual agonist tirzepatide, which activates a second incretin receptor alongside GLP-1.

How the class works on weight

These medications act on appetite regulation, satiety signaling, and gastric emptying, lowering caloric intake through mechanism-mediated changes rather than sheer willpower. The degree of body-weight reduction depends on the specific compound, dose, adherence, and individual factors. Approved weight-management dosing is titrated upward from a starting point over several weeks per each product's label.

The evidence base and where it lives

The trials worth consulting map to specific compounds: SURMOUNT and SURPASS for tirzepatide, STEP and SUSTAIN for semaglutide, AWARD for dulaglutide, and LEAD and LEADER for liraglutide. Effect sizes on body weight, A1C, and cardiovascular endpoints vary by population, dose, and primary endpoint. Much of this work appears in The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology.

Approved products and their uses

Indications differ by product: type 2 diabetes for most, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several, and obstructive sleep apnea in adults with obesity for Zepbound as of 2024. The FDA label governs which product is prescribed for which indication, so specifics belong in a provider discussion.

The shared safety warnings

All of these medications carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies and are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal and peak during dose escalation; rare serious events include pancreatitis, gallbladder disease, and acute kidney injury tied to dehydration.

Where your genetics enter the conversation

Even the best-studied medication is prescribed into a body whose metabolic terrain is set partly by genes. The receptor these drugs bind, GLP1R, varies from person to person in ways that influence receptor density and how efficiently the incretin signal travels downstream. Nearby, FTO shapes appetite regulation and where the body sets its adiposity baseline, MC4R governs satiety signaling inside the hypothalamus and total energy intake, and TCF7L2 is tied to insulin secretion and incretin response. FTO shapes appetite and adiposity set-point, while TCF7L2 links to glucose homeostasis and GLP-1 secretion.

None of these variants forecast how you will respond to a particular medication, and the analysis is not pharmacogenomic. What they do is describe the metabolic terrain a clinician is working within. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across FTO and MC4R, and TCF7L2 — pathway-level context you bring to a provider conversation, never a prediction of drug response or dose. It is the test before you invest idea applied to metabolic care.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — including Semaglutide Injection and Tirzepatide Injection. It does not sell other GLP-1-category compounds. For deeper reading, see GLP-1 Receptor Agonist.

The bottom line: GLP medications are best understood as one incretin-based class with a deep, well-published evidence base and a consistent set of warnings. Products differ by indication and format, but the mechanism and safety scaffolding are shared. The genetic terrain beneath them is what makes any prescription genuinely individual.

Frequently Asked Questions

What makes something a GLP medication?

It is a compound that engages the GLP-1 receptor to reproduce the incretin hormone's effects on insulin, gastric emptying, and satiety. The category includes single-agonist GLP-1 drugs such as semaglutide and the dual GIP/GLP-1 agonist tirzepatide, which activates a second incretin receptor as well.

Where is the evidence published?

Much of it appears in The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology, drawn from programs like SURMOUNT, SURPASS, STEP, SUSTAIN, AWARD, LEAD, and LEADER. Effect sizes vary by population, dose, and endpoint, so relevant outcomes are best reviewed with a provider.

Are GLP medications safe?

Each has a characterized safety profile from its trial program and post-marketing surveillance, and all carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies. Common side effects are gastrointestinal; rare serious events include pancreatitis and gallbladder disease. Personal history should be reviewed with a provider.

Can a genetic test choose a GLP medication for me?

No. The Precision Peptide Genetic Test never predicts response to any medication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — upstream context for the broader protocol conversation, not a recommendation of any specific product.

Keep exploring the PlexusDx Education Hub for more GLP-1 and metabolic-health explainers. Return to the Education Hub.